loading
前日終値:
$2.73
開ける:
$2.74
24時間の取引高:
1.46M
Relative Volume:
0.59
時価総額:
$251.78M
収益:
$32.31M
当期純損益:
$-237.09M
株価収益率:
-0.9722
EPS:
-2.88
ネットキャッシュフロー:
$-219.11M
1週間 パフォーマンス:
-7.59%
1か月 パフォーマンス:
-16.67%
6か月 パフォーマンス:
+45.83%
1年 パフォーマンス:
-26.12%
1日の値動き範囲:
Value
$2.7324
$2.921
1週間の範囲:
Value
$2.60
$3.08
52週間の値動き範囲:
Value
$0.9101
$4.12

Editas Medicine Inc Stock (EDIT) Company Profile

Name
名前
Editas Medicine Inc
Name
セクター
Healthcare (1157)
Name
電話
617-401-9000
Name
住所
11 HURLEY ST., CAMBRIDGE, MA
Name
職員
226
Name
Twitter
@editasmed
Name
次回の収益日
2025-08-08
Name
最新のSEC提出書
Name
EDIT's Discussions on Twitter

EDIT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EDIT
Editas Medicine Inc
2.80 245.48M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-28 開始されました H.C. Wainwright Buy
2024-12-16 ダウングレード JP Morgan Neutral → Underweight
2024-12-13 ダウングレード Chardan Capital Markets Buy → Neutral
2024-12-13 ダウングレード Stifel Buy → Hold
2024-12-13 ダウングレード Truist Buy → Hold
2024-12-11 ダウングレード Wells Fargo Overweight → Equal Weight
2024-11-25 ダウングレード BofA Securities Buy → Underperform
2024-11-06 アップグレード Evercore ISI In-line → Outperform
2024-11-04 ダウングレード Raymond James Outperform → Mkt Perform
2024-08-08 アップグレード BofA Securities Neutral → Buy
2024-05-09 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-10-24 アップグレード Citigroup Neutral → Buy
2023-10-18 アップグレード JP Morgan Underweight → Neutral
2023-10-17 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-09-29 アップグレード Stifel Hold → Buy
2023-06-12 アップグレード Raymond James Mkt Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2022-12-13 開始されました Citigroup Neutral
2022-12-06 再開されました Credit Suisse Neutral
2022-11-18 ダウングレード Credit Suisse Outperform → Neutral
2022-11-18 ダウングレード Oppenheimer Outperform → Perform
2022-09-29 開始されました BofA Securities Neutral
2021-10-19 開始されました SVB Leerink Mkt Perform
2021-09-24 開始されました Stifel Hold
2021-09-10 アップグレード Oppenheimer Perform → Outperform
2021-08-09 アップグレード Truist Hold → Buy
2021-08-05 アップグレード Evercore ISI Underperform → Outperform
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-04 開始されました RBC Capital Mkts Sector Perform
2021-04-16 開始されました Goldman Sell
2021-03-22 開始されました Credit Suisse Outperform
2021-03-01 ダウングレード Barclays Overweight → Equal Weight
2021-02-26 ダウングレード Truist Buy → Hold
2021-01-19 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-01-07 ダウングレード Raymond James Outperform → Mkt Perform
2020-12-10 アップグレード Wells Fargo Equal Weight → Overweight
2020-11-03 開始されました Robert W. Baird Underperform
2020-06-18 再開されました SunTrust Buy
2020-02-21 開始されました Wells Fargo Equal Weight
2019-04-12 開始されました Evercore ISI Outperform
2018-10-10 開始されました Guggenheim Neutral
2018-09-21 開始されました Raymond James Outperform
2018-05-15 繰り返されました Chardan Capital Markets Buy
2018-02-13 開始されました CLSA Underperform
2018-01-23 アップグレード SunTrust Hold → Buy
2017-07-14 開始されました SunTrust Hold
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-10 アップグレード Jefferies Hold → Buy
2016-06-02 開始されました Jefferies Hold
2016-02-29 開始されました JMP Securities Mkt Outperform
2016-02-29 開始されました JP Morgan Neutral
2016-02-29 開始されました Morgan Stanley Equal-Weight
すべてを表示

Editas Medicine Inc (EDIT) 最新ニュース

pulisher
Aug 20, 2025

Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Editas Medicine Inc. Moves Into Overbought Range Analysts CautiousPrice Action & Stepwise Swing Trade Plans - beatles.ru

Aug 20, 2025
pulisher
Aug 19, 2025

Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results - MarketBeat

Aug 19, 2025
pulisher
Aug 18, 2025

Editas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00 at Robert W. Baird - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Short interest data insights for Editas Medicine Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

Intraday pattern recognizer results for Editas Medicine Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to recover losses in Editas Medicine Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Ranking Editas Medicine Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to build a custom watchlist for Editas Medicine Inc.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Trend analysis for Editas Medicine Inc. this weekWeekly Trend Recap & Comprehensive Market Scan Insights - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

What makes Editas Medicine Inc. stock price move sharplyTrend Reversal & High Accuracy Buy Signal Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Is Editas Medicine Inc. showing signs of accumulationMarket Growth Review & High Accuracy Buy Signal Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

HC Wainwright Boosts Editas Medicine Price Target to $5.00, Analysts Predict 22.47% Upside - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Editas Medicine's Q2 Earnings Boost Stock Price 34% Amid Plans to Nominate First In Vivo Development Candidate in September - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street Zen - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

Why Editas Medicine Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & Free Verified High Yield Trade Plans - sundaytimes.kr

Aug 15, 2025
pulisher
Aug 15, 2025

Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

What drives Editas Medicine Inc.’s stock priceProduct Launch & Daily Technical Stock Forecast Reports - thegnnews.com

Aug 15, 2025
pulisher
Aug 15, 2025

Why Editas Medicine Stock Was Skyrocketing This Week - AOL.com

Aug 15, 2025
pulisher
Aug 15, 2025

H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress - Investing.com Canada

Aug 15, 2025
pulisher
Aug 15, 2025

Editas Medicine: HC Wainwright Raises PT to $5, Maintains Buy Rating - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Robert W. Baird Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - Defense World

Aug 15, 2025
pulisher
Aug 14, 2025

How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceMarket Movement Recap & Daily Profit Focused Stock Screening - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Applications Of Genetic Engineering Market is Booming Worldwide | Editas Medicine , Intellia Therapeutics - newstrail.com

Aug 14, 2025
pulisher
Aug 14, 2025

Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Weekly Chart Analysis and Trade Guides - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 13, 2025

Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine shares surge 28.87% intraday after strong Q2 earnings and positive analyst ratings. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈

Aug 13, 2025
pulisher
Aug 13, 2025

Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Editas: Q2 Earnings Snapshot - Greenwich Time

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

What high frequency data says about Editas Medicine Inc.2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan

Aug 12, 2025

Editas Medicine Inc (EDIT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Editas Medicine Inc (EDIT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Jul 31 '25
Sale
2.49
5,121
12,757
64,398
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
大文字化:     |  ボリューム (24 時間):